<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586504</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS7996</org_study_id>
    <nct_id>NCT04586504</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children</brief_title>
  <official_title>Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emergency Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mailman School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-finding study to compare intranasal midazolam doses of 0.2, 0.3, 0.4 and 0.5 mg/kg in&#xD;
      children undergoing laceration repair to achieve the following aims:&#xD;
&#xD;
      Specific Aim #1: To determine the most effective dose of intranasal midazolam for producing&#xD;
      adequate sedation state and time to onset of minimal sedation associated with each dose.&#xD;
&#xD;
      Specific Aim #2: To determine the time to recovery and describe the adverse events associated&#xD;
      with each dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intranasal midazolam is a common and effective sedative whose use in children presenting to&#xD;
      emergency departments has been described. However, the doses of intranasal midazolam used&#xD;
      have varied greatly, with no identified optimal dose. Doses most commonly described in&#xD;
      literature reviews, research studies, and clinical guidelines range from 0.2 to 0.5 mg/kg.&#xD;
      There is only one study, retrospective, that compares doses and suggests that clinical&#xD;
      efficacy is improved with higher doses, without any clear difference in safety. There is a&#xD;
      need for a rigorously-conducted trial to determine the dose of intranasal midazolam that&#xD;
      optimizes the adequacy of sedation state without leading to adverse events or compromising&#xD;
      emergency department-centric outcomes such as time to onset of sedation and time to recovery.&#xD;
      To fill this important and persistent gap in knowledge, the investigator will conduct a&#xD;
      dose-finding study using an adaptive trial design to compare intranasal midazolam doses of&#xD;
      0.2, 0.3, 0.4, and 0.5 mg/kg in children undergoing laceration repairs, one of the most&#xD;
      common types of minor trauma treated in emergency departments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sequential selection procedure</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Sedation State Scale Score</measure>
    <time_frame>From study drug administration until procedure finished (approximately 60 minutes)</time_frame>
    <description>The Pediatric Sedation State Scale (PSSS) is scored from 0 to 5, representing a continuum of sedation that spans from over-sedation associated with changes in vital signs (0) to inadequate sedation (5).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of minimal sedation</measure>
    <time_frame>From study drug administration until procedure finished (approximately 60 minutes)</time_frame>
    <description>Time (in minutes) from administration of intranasal midazolam until a University of Michigan Sedation State (UMSS) score of 1 is achieved. The UMSS represents a spectrum of depth of sedation ranging from unarousable (4) to awake and alert (0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>From study drug administration until patient discharge (approximately 120 minutes)</time_frame>
    <description>Time (in minutes) from procedure completion until a Simplified Aldrete Score (SAS) of at least 6 is achieved. The score ranges from 0 (lowest) to 8 (highest). If a patient already fulfills criteria for recovery at procedure start, then time to recovery is 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From study drug administration until patient discharge (approximately 120 minutes)</time_frame>
    <description>Adverse events will be defined using the Pediatric Emergency Research Canada and Pediatric Emergency Care Applied Research Network Consensus-Based Recommendations. These adverse events include oxygen desaturation; apnea (central, obstructive, laryngospasm); clinically apparent pulmonary aspiration; retching/vomiting; bradycardia; hypotension; excitatory movements; paradoxical response to sedation; unpleasant recovery reactions; and permanent complications (including death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSBD-R Scale Score</measure>
    <time_frame>From study drug administration until procedure finished (approximately 60 minutes)</time_frame>
    <description>Procedural pain and distress will be measured using the Observational Scale of Behavioral Distress - Revised (OSBD-R). Each 15-second interval is scored from 0 (no pain or distress) to 23.5 (maximal pain and distress).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UMSS Scale Score</measure>
    <time_frame>From study drug administration until procedure finished (approximately 60 minutes)</time_frame>
    <description>Depth of sedation will be measured using the University of Michigan Sedation Scale (UMSS). This sedation scale ranges from zero to four with higher numbers indicating deeper sedation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Procedural Anxiety</condition>
  <arm_group>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.3 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.5 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal midazolam</intervention_name>
    <description>5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.</description>
    <arm_group_label>0.2 mg/kg</arm_group_label>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_label>0.4 mg/kg</arm_group_label>
    <arm_group_label>0.5 mg/kg</arm_group_label>
    <other_name>IN midazolam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 6 months to 7 years old (i.e. before their 8th birthday)&#xD;
&#xD;
          -  Simple laceration&#xD;
&#xD;
          -  Attending physician has decided intranasal midazolam indicated to facilitate repair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Repair using tissue adhesive (e.g. Dermabond) or staples&#xD;
&#xD;
          -  Known or confirmed developmental delay&#xD;
&#xD;
          -  Baseline motor neurological abnormality (e.g. motor deficit, cerebral palsy)&#xD;
&#xD;
          -  Autism spectrum disorder&#xD;
&#xD;
          -  Illness associated with chronic pain&#xD;
&#xD;
          -  Known allergy to midazolam or any other benzodiazepine&#xD;
&#xD;
          -  Eyelid laceration&#xD;
&#xD;
          -  Tongue or intraoral lacerations&#xD;
&#xD;
          -  Nasal obstruction that cannot be easily cleared&#xD;
&#xD;
          -  Does not speak English or Spanish&#xD;
&#xD;
          -  Foster children, wards of the state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <phone>212-305-9825</phone>
    <email>dst2141@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raquel Shrager</last_name>
    <phone>212-305-4687</phone>
    <email>rs3823@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NewYork Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel S Tsze, MD, MPH</last_name>
      <phone>212-305-9825</phone>
      <email>dst2141@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raquel Shrager</last_name>
      <phone>212-305-4687</phone>
      <email>rs3823@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel S Tsze, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter S Dayan, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hilary A Woodward, MS, CCLS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Shiun Leu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tsze DS, Ieni M, Fenster DB, Babineau J, Kriger J, Levin B, Dayan PS. Optimal Volume of Administration of Intranasal Midazolam in Children: A Randomized Clinical Trial. Ann Emerg Med. 2017 May;69(5):600-609. doi: 10.1016/j.annemergmed.2016.08.450. Epub 2016 Nov 4.</citation>
    <PMID>27823876</PMID>
  </reference>
  <reference>
    <citation>Cravero JP, Askins N, Sriswasdi P, Tsze DS, Zurakowski D, Sinnott S. Validation of the Pediatric Sedation State Scale. Pediatrics. 2017 May;139(5). pii: e20162897. doi: 10.1542/peds.2016-2897.</citation>
    <PMID>28557732</PMID>
  </reference>
  <reference>
    <citation>Mellion SA, Bourne D, Brou L, Brent A, Adelgais K, Galinkin J, Wathen J. Evaluating Clinical Effectiveness and Pharmacokinetic Profile of Atomized Intranasal Midazolam in Children Undergoing Laceration Repair. J Emerg Med. 2017 Sep;53(3):397-404. doi: 10.1016/j.jemermed.2017.05.029.</citation>
    <PMID>28992870</PMID>
  </reference>
  <reference>
    <citation>Leu C-S, Levin B. On the probability of correct selection in the Levin-Robbins sequential elimination procedure. Stat Sin 1999;9(3):879-91.</citation>
  </reference>
  <reference>
    <citation>Malviya S, Voepel-Lewis T, Tait AR, Merkel S, Tremper K, Naughton N. Depth of sedation in children undergoing computed tomography: validity and reliability of the University of Michigan Sedation Scale (UMSS). Br J Anaesth. 2002 Feb;88(2):241-5.</citation>
    <PMID>11878656</PMID>
  </reference>
  <reference>
    <citation>Bhatt M, Kennedy RM, Osmond MH, Krauss B, McAllister JD, Ansermino JM, Evered LM, Roback MG; Consensus Panel on Sedation Research of Pediatric Emergency Research Canada (PERC) and the Pediatric Emergency Care Applied Research Network (PECARN). Consensus-based recommendations for standardizing terminology and reporting adverse events for emergency department procedural sedation and analgesia in children. Ann Emerg Med. 2009 Apr;53(4):426-435.e4. doi: 10.1016/j.annemergmed.2008.09.030. Epub 2008 Nov 20.</citation>
    <PMID>19026467</PMID>
  </reference>
  <reference>
    <citation>Elliott CH, Jay SM, Woody P. An observation scale for measuring children's distress during medical procedures. J Pediatr Psychol. 1987 Dec;12(4):543-51.</citation>
    <PMID>3430286</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Daniel S Tsze, MD, MPH</investigator_full_name>
    <investigator_title>Associate Professor of Emergency Medicine, Dept of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Intranasal</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Laceration repair</keyword>
  <keyword>Sedation</keyword>
  <keyword>Anxiolysis</keyword>
  <keyword>Adaptive trial design</keyword>
  <keyword>Dose finding</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

